Thrombosis
Conditions
Brief summary
As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of bleeding) or a low INR (with a risk of thrombosis)
Detailed description
The results of this project will benefit in (1) Identification of novel features or mutation types in warfarin resistance genomes. (2) To determine whether other polymorphisms in noncoding regions or their unique haplotype combinations contribute to the variability in the maintenance dose of warfarin, and (3)personalization of the drug and deciding the correct dose from the start.
Interventions
DIAGNOSTIC_TESTGenetic Mutations
By next generation sequencing
Sponsors
Tanta University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with thrombosis and warfarin resistance
Exclusion criteria
* less than 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of patients with genetic polymorphism | 6 months | patients with abnormal polymorphisms |
Countries
Egypt
Contacts
Primary ContactAmr Gawaly, Ass Prof
Outcome results
None listed